# US 2019/0167587 A1 · Pharmaceutical composition for prevention or treatment of pulmonary disease including mesenchymal stem cell-derived artificial nanosomes

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2019/0167587 A1
- Document ID: US20190167587A1
- Status: Published application
- Kind: A1
- Application number: 16/205,277
- Filed: 2018-11-30
- Published: 2019-06-06
- Earliest claimed: 2017-12-01
- Assignees: Mdimune Inc.
- Applicants: Mdimune Inc.
- Inventors: Shin Gyu BAE; Yeon-Mok OH
- Web page: https://patentgrep.com/patent/US20190167587A1

## CPC

- A61K 9/1271: Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers (liposomes as conjugates {A61K47/6911})
- A61K 9/1277: Preparation processes; Proliposomes
- A61K 35/28: Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
- A61P 11/00: Drugs for disorders of the respiratory system
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

Provided herein is a method for treating a pulmonary disease using mesenchymal stem cell-derived artificial nanosomes exhibiting a significantly excellent capability to regenerate alveoli compared to mesenchymal stem cells themselves and natural exosomes derived from human adipose-derived mesenchymal stem cells, wherein the mesenchymal stem cell-derived artificial nanosomes of the present disclosure may be collected through a simple production method using an extruder and an ultracentrifuge, instead of treating mesenchymal stem cells with a separate chemical substance and the potential side effects caused by stem cell therapeutic agents is low.

## Claims

### Claim 1

A method of treating a pulmonary diseases in a subject in need thereof comprising administering an effective amount of artificial nanosomes derived from mesenchymal stem cells to the subject.

### Claim 2 (depends on 1)

The method of claim 1, wherein the artificial nanosomes derived from mesenchymal stem cells induce regeneration of alveoli.

### Claim 3 (depends on 1)

The method of claim 1, wherein the mesenchymal stem cells are mesenchymal stem cells derived from fat, umbilical cord, umbilical cord blood, or bone marrow.

### Claim 4 (depends on 1)

The method of claim 1, wherein the artificial nanosomes derived from mesenchymal stem cells are produced using an extruder and an ultracentrifuge.

### Claim 5 (depends on 1)

The method of claim 1, wherein the pulmonary disease comprises at least one selected from the group consisting of emphysema, chronic bronchitis, pneumonia, pulmonary hypertension, chronic obstructive pulmonary disease, and asthma.

### Claim 6 (depends on 5)

The method of claim 5, wherein the emphysema comprises at least one selected from the group consisting of panlobular emphysema, centrilobular emphysema, interstitial emphysema, and compensatory emphysema.

### Claim 7 (depends on 1)

The method of claim 1, wherein the artificial nanosomes derived from mesenchymal stem cells increase expression of a growth factor.
